These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 16420078

  • 1. Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine.
    Nelson JC, Portera L, Leon AC.
    J Clin Psychiatry; 2005 Nov; 66(11):1409-14. PubMed ID: 16420078
    [Abstract] [Full Text] [Related]

  • 2. Are there differences in the symptoms that respond to a selective serotonin or norepinephrine reuptake inhibitor?
    Nelson JC, Portera L, Leon AC.
    Biol Psychiatry; 2005 Jun 15; 57(12):1535-42. PubMed ID: 15953490
    [Abstract] [Full Text] [Related]

  • 3. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder.
    Versiani M, Mehilane L, Gaszner P, Arnaud-Castiglioni R.
    J Clin Psychiatry; 1999 Jun 15; 60(6):400-6. PubMed ID: 10401920
    [Abstract] [Full Text] [Related]

  • 4. Reboxetine versus fluoxetine: an overview of efficacy and tolerability.
    Massana J.
    J Clin Psychiatry; 1998 Jun 15; 59 Suppl 14():8-10. PubMed ID: 9818624
    [Abstract] [Full Text] [Related]

  • 5. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression.
    Andreoli V, Caillard V, Deo RS, Rybakowski JK, Versiani M.
    J Clin Psychopharmacol; 2002 Aug 15; 22(4):393-9. PubMed ID: 12172339
    [Abstract] [Full Text] [Related]

  • 6. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
    Fava M, McGrath PJ, Sheu WP, Reboxetine Study Group.
    J Clin Psychopharmacol; 2003 Aug 15; 23(4):365-9. PubMed ID: 12920412
    [Abstract] [Full Text] [Related]

  • 7. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning.
    Dubini A, Bosc M, Polin V.
    J Psychopharmacol; 1997 Aug 15; 11(4 Suppl):S17-23. PubMed ID: 9438229
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: a single-blind, randomized clinical trial.
    Taner E, Demir EY, Cosar B.
    Adv Ther; 2006 Aug 15; 23(6):974-87. PubMed ID: 17276965
    [Abstract] [Full Text] [Related]

  • 9. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.
    Baldwin D, Bridgman K, Buis C.
    J Psychopharmacol; 2006 Jan 15; 20(1):91-6. PubMed ID: 16204325
    [Abstract] [Full Text] [Related]

  • 10. Do noradrenaline and serotonin differentially affect social motivation and behaviour?
    Dubini A, Bosc M, Polin V.
    Eur Neuropsychopharmacol; 1997 Apr 15; 7 Suppl 1():S49-55; discussion S71-3. PubMed ID: 9169310
    [Abstract] [Full Text] [Related]

  • 11. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder.
    Versiani M, Cassano G, Perugi G, Benedetti A, Mastalli L, Nardi A, Savino M.
    J Clin Psychiatry; 2002 Jan 15; 63(1):31-7. PubMed ID: 11838623
    [Abstract] [Full Text] [Related]

  • 12. Chairman's overview. The place of reboxetine in antidepressant therapy.
    Montgomery SA.
    J Clin Psychiatry; 1998 Jan 15; 59 Suppl 14():26-9. PubMed ID: 9818628
    [Abstract] [Full Text] [Related]

  • 13. The impact of antidepressant use on social functioning: reboxetine versus fluoxetine.
    Venditti LN, Arcelus A, Birnbaum H, Greenberg P, Barr CE, Rowland C, Williamson T.
    Int Clin Psychopharmacol; 2000 Sep 15; 15(5):279-89. PubMed ID: 10993130
    [Abstract] [Full Text] [Related]

  • 14. Effect of reboxetine on major depressive disorder in breast cancer patients: an open-label study.
    Grassi L, Biancosino B, Marmai L, Righi R.
    J Clin Psychiatry; 2004 Apr 15; 65(4):515-20. PubMed ID: 15119914
    [Abstract] [Full Text] [Related]

  • 15. Effects of reboxetine on Hamilton Depression Rating Scale factors from randomized, placebo-controlled trials in major depression.
    Ferguson JM, Mendels J, Schwart GE.
    Int Clin Psychopharmacol; 2002 Mar 15; 17(2):45-51. PubMed ID: 11890185
    [Abstract] [Full Text] [Related]

  • 16. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
    Davidson JR, Meoni P, Haudiquet V, Cantillon M, Hackett D.
    Depress Anxiety; 2002 Mar 15; 16(1):4-13. PubMed ID: 12203668
    [Abstract] [Full Text] [Related]

  • 17. Fluoxetine treatment of depressed patients with comorbid anxiety disorders.
    Sonawalla SB, Farabaugh A, Johnson MW, Morray M, Delgado ML, Pingol MG, Rosenbaum JF, Fava M.
    J Psychopharmacol; 2002 Sep 15; 16(3):215-9. PubMed ID: 12236627
    [Abstract] [Full Text] [Related]

  • 18. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder.
    Massana J, Möller HJ, Burrows GD, Montenegro RM.
    Int Clin Psychopharmacol; 1999 Mar 15; 14(2):73-80. PubMed ID: 10220121
    [Abstract] [Full Text] [Related]

  • 19. Effect of reboxetine on depression in Parkinson's disease patients.
    Lemke MR.
    J Clin Psychiatry; 2002 Apr 15; 63(4):300-4. PubMed ID: 12000202
    [Abstract] [Full Text] [Related]

  • 20. Clinical efficacy of reboxetine in major depression.
    Schatzberg AF.
    J Clin Psychiatry; 2000 Apr 15; 61 Suppl 10():31-8. PubMed ID: 10910015
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.